Ionis Pharmaceuticals, Inc. (IONS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Ionis Pharmaceuticals, Inc. (IONS) is down 7.8% since the beginning of the year. At $73 per share, IONS is trading 15.9% below its 52-week high of $87. Investors who bought $1,000 worth of IONS shares 5 years ago would now be looking at an investment worth $2,101.

Ionis Pharmaceuticals, Inc. (IONS) has returned -7.76% so far this year and 113.93% over the past 12 months. Over the last ten years, IONS has returned 12.26% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since May 17, 1991, IONS's average daily return is +0.10%, while the average monthly return is +1.92%. At this rate, an investment would double in approximately 3.0 years.

Historically, 50% of months were positive and 50% were negative. The best month was Nov 1992 with a return of +91.7%, while the worst month was Dec 1999 at -59.2%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, IONS closed higher 47% of trading days. The best single day was Aug 22, 2001 with a return of +47.7%, while the worst single day was Dec 15, 1999 at -63.9%.

Ionis Pharmaceuticals, Inc. has an annualized alpha of 15.35%, beta of 1.09, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since May 20, 1991.

• This stock participated in 140.53% of S&P 500 Index downside but only 134.89% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IONS ranks 93 for risk / return — in the top 93% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Ionis Pharmaceuticals, Inc. (IONS) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Ionis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Ionis Pharmaceuticals, Inc. was 91.42%, occurring on May 17, 2005. Recovery took 2051 trading sessions.

The current Ionis Pharmaceuticals, Inc. drawdown is 15.64%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Ionis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Ionis Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.